- Home
- BGLC vs FTFT Comparison
BGLC vs FTFT Comparison
Compare BGLC & FTFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- FTFT
- Stock Information
- Founded
- BGLC 2017
- FTFT N/A
- Country
- BGLC Malaysia
- FTFT United States
- Employees
- BGLC N/A
- FTFT N/A
- Industry
- BGLC Medical Specialities
- FTFT Business Services
- Sector
- BGLC Health Care
- FTFT Consumer Discretionary
- Exchange
- BGLC Nasdaq
- FTFT Nasdaq
- Market Cap
- BGLC 7.6M
- FTFT N/A
- IPO Year
- BGLC N/A
- FTFT N/A
- Fundamental
- Price
- BGLC $0.37
- FTFT $0.33
- Analyst Decision
- BGLC
- FTFT
- Analyst Count
- BGLC 0
- FTFT 0
- Target Price
- BGLC N/A
- FTFT N/A
- AVG Volume (30 Days)
- BGLC 117.9K
- FTFT 141.3K
- Earning Date
- BGLC 11-20-2024
- FTFT 11-18-2024
- Dividend Yield
- BGLC N/A
- FTFT N/A
- EPS Growth
- BGLC N/A
- FTFT N/A
- EPS
- BGLC N/A
- FTFT N/A
- Revenue
- BGLC $9,183,168.00
- FTFT $37,105,708.00
- Revenue This Year
- BGLC N/A
- FTFT N/A
- Revenue Next Year
- BGLC N/A
- FTFT N/A
- P/E Ratio
- BGLC N/A
- FTFT N/A
- Revenue Growth
- BGLC N/A
- FTFT 84.77
- 52 Week Low
- BGLC $0.31
- FTFT $0.29
- 52 Week High
- BGLC $3.39
- FTFT $2.60
- Technical
- Relative Strength Index (RSI)
- BGLC 32.80
- FTFT 48.55
- Support Level
- BGLC $0.38
- FTFT $0.30
- Resistance Level
- BGLC $0.49
- FTFT $0.37
- Average True Range (ATR)
- BGLC 0.02
- FTFT 0.03
- MACD
- BGLC -0.01
- FTFT -0.00
- Stochastic Oscillator
- BGLC 5.94
- FTFT 39.25
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.